Índice 2024-5, MED contra el Cáncer que pronto estarán comercializados

Antonio Iñesta. Blog Web2.0 y Salud http://fecoainesta.blogspot.com.es/

Esta es la cuarta parte del Índice de los Blogs publicados en 2024.

*Medicamentos contra el Cáncer aprobados en 2024

*Índice principios activos de los MED contra el Cáncer aprobados en 2024

*Clasificación y Nombre comercial de los MED contra el Cáncer aprobados en 2024

*Medicamentos contra el Cáncer por Indicaciones, en 2024

*Medicamentos contra el Cáncer que pronto estarán comercializados

*Pruebas de diagnóstico acompañante de los MED contra el Cáncer aprobados en 2024

Medicamentos contra el Cáncer que pronto estarán comercializados 2024

Cáncer, EEUU, España, Inmunoterapia, Medicamentos, Salud, Tramite de registro, Unión Europea. Blogs: 31/12/2024, 3/12/24, 3/11/24, 3/10/24, 4/09/24, 3/08/24, 3/07/24, 3/06/2024, 3/05/2024, 3/04/2024, 4/03/2024, 5/02/2024.

New Drug Application (NDA, Solicitud de nuevo medicamento); supplemental NDA (sNDA, Solicitud de nuevo medicamento complementaria); Biologics License Application (BLA, Solicitud de licencia de productos biológicos); supplemental BLA (sBLA, Solicitud de licencia de productos biológicos complementaria); Rare Pediatric Disease designation (RPDD); Regenerative Medicine Advanced Therapy; presentación de NDA o de BLA a la FDA; Investigational NDA; Fast Track (Vía rápida); Breakthrough Therapy (Terapia innovadora); Priority Review (Revisión prioritaria). Resaltado en el nombre comercial significa Comercializado no con las mismas indicaciones. alo = alogénico, que procede de otro individuo de la misma especie del que lo recibe.

*9MW2821 (Mabwell)(ADCanti Nectina-4), Blog 4/03/2024;

*ACE2016 (Acepodia)(aloCelTγδ2anti EGFR), Blog 4/03/2024; Acalabrutinib (Calquence, AstraZeneca/Acerta Pharma BV; FDA; EMA, España DH), Blog 3/11/2024; Actinio (Ac-225) FL-02 (Full-Life Technologies)(RadFarm), Blog 3/08/2024; ACT-IOP-003 (Focal Medical, Inc.)(iontoforético), Blog 5/02/2024; ACTM-838 (Actym Therapeutics)(Terapia Gen), Blog 3/06/2024; Adagrasib (Krazati, Mirati Therapeutics, Inc.)(5.Inh KRAS/G12C) con cetuximab (Erbitux, Merk KGaA; FDA, EMA, España UH)(Anti EGFR), Blog 4/03/2024; ADI-270 (Adicet Bio)(aloCarTAnti CD70), Blog 3/08/2024; ADRX-0405 (Adcentrx Therapeutics)(ADCanti STEAP1), Blog 3/11/2024; Afamitresgén autoleucel (afami-cel, Tecelra, Adaptimmune)(TcrTAnti MAGE-A4), Blog 5/02/2024; AFM24 (Affimed)(AcMB CD16A/EGFR) más atezolizumab (Tecentriq, Genentech; FDA, EMA, España UH)(Anti PD-L1), Blog 3/06/2024; AGuIX (NH TherAguix)(gadolinio), Blog 3/06/2024; ALE.P02 (Alentis Therapeutics)(ADCanti CLDN1), Blog 3/12/2024; APG-157 (Aveta Biomics)(inmuno-oncológico), Blog 4/09/2024; AS1986NS (Antelope Surgical Solutions, Inc.)(lutecio-175), Blog 3/12/2024; Asciminib (Scemblix, Novartis AG; FDA, EMA, España DH)(2.1.Inh BCR-ABL), Blog 3/08/2024; Avutometinib (Verastem Oncology)(3.2.Inh MEK) y sotorasib (Lumakras, Amgen, Inc.; FDA, EMA, España DH)(5.Inh KRAS/G12C);

*BAT8006 (Bio-Thera Solutions)(ADC FRα), Blog 3/04/2024; BAY 2927088 (Bayer)(1.1.Inh HER2), Blog 4/03/2024; Belantamab mafodotina (Blenrep, GSK plc.) ADCanti BCMA) en combinación con bortezomib y dexametasona, así como con pomalidomida y dexametasona, Blog 3/12/2024; BGB-16673 (BeiGene, Ltd.)(CDACanti BTK), Blog 4/09/2024; BNT324/DB-1311 (BioNTech)(AcMB B7/H3), Blog 3/08/2024; BSI-082 (Biosion)(Anti-SIRPα), Blog 5/02/2024; BST02 (Biosyngen)(TerTIL), Blog 4/03/2024; BTX-9341 (Biotheryx, Inc.)(3.7.Inh CDK4/6), Blog 3/06/2024; BXCL701 (Talabostat, BioXcel Therapeutics)(Inh Dipeptidil peptidasa 4/8/9) con un inhibidor de punto de control inmune, Blog 4/03/2024;

*Cabozantinib (Cabometyx, Exelixis, Inc.)(1.5.Inh Met), Blog 4/09/2024; CLN-619 (Cullinan Oncology, Inc.)(Anti MICA/B), Blog 3/04/2024; Cobre (Cu-64) SAR-bisPSMA (Clarity Pharmaceuticals)(RadFarm), Blog 4/09/2024; CRB-701 (SYS6002, Corbus Pharmaceuticals), Blog 31/12/2024; CT-0525 (Carisma Therapeutics)(CARmonocitAnti HER2), Blog 3/07/24;

*Darolutamida (Nubeqa, Bayer; FDA; EMA; España DH) en combinación con terapia de deprivación de andrógenos, Blog 3/12/2024; Dasatinib (Dasynoc, Xspray Pharma AB)(2.1.Inh BCR-ABL), Blog 4/03/2024; Datopotamab deruxtecan (Dato-DXd, AstraZeneca)(ADCanti TROP2), Blogs: 3/12/2024, 3/05/2024, 4/03/2024; Deltacel (KB-GDT-01, Kiromic BioPharma)(aloTerCelTγδ) en combinación con radioterapia de dosis baja, Blog 4/09/2024; DOC1021(Diakonos Oncology Corporation)(Vac cel dendríticas), Blog 3/08/2024; Dostarlimab-gxly (Jemperli, GlaxoSmithKline LLC; FDA (-gxly), EMA, España UH), Blog 31/12/2024; Dostarlimab (Jemperli, GlaxoSmithKline LLC; FDA (-gxly), EMA, España UH)(Anti PD-1) con quimioterapia, Blog 3/05/2024; DSP-5336 (Sumitomo Pharma)(9.Inh Menina), Blog 3/08/2024; Durvalumab (Imfinzi, AstraZeneca)(Anti PD-L1), Blogs: 31/12/2024, 4/09/2024;

*EIS-12656 (Eisbach Bio GmbH)(Inh CHD1L), Blog 3/06/2024; Elraglusib (9-ING-41, Actuate Therapeutics)(Inh GSK3), Blog 3/12/2024; Ensartinib (Xcovery Holdings, Inc.)(1.3,2ªgen.Inh Alk), Blog 3/04/2024; EO-3021 (Elevation Oncology, Inc.)(ADC), Blog 3/10/2024; Epcoritamab-bysp (Epkinly, AbbVie/Genmab US, Inc.)(AcMB CD20/CD3), Blog 4/03/2024;

*Galinpepimut-S (GPS, Sellas Life Sciences Group)(Vacuna), Blog 3/11/2024; Glofitamab-gxbm (Columvi, Roche) en combinación con gemcitabina y oxaliplatino (GemOx), Blog 31/12/2024; GSK5764227 (GSK’227; HS-20093, GSK plc.)(ADCanti B7-H3), Blog 4/09/2024;

*HBM9027 (Harbour BioMed)(AcMB PD-L1/CD40), Blog 5/02/2024; HC-7366 (HiberCell)(Modul GCN2), Blog 3/11/2024;

*IBI363 (Innovent Biologics)(AcMB PD-1/IL-2α), Blog 3/10/2024; ICT01 (ImCheck Therapeutics)(AcManti BTN3A) más azacitidina y venetoclax (Venclexta), Blog 3/10/2024; IDP-023 (Indapta Therapeutics)(TerNK), Blog 4/03/2024; IMC001 (Immunofoco)(CarTAnti EpCAM), Blog 4/03/2024; IMM-1-104 (Immuneering Corporation)(3.vía MAPK), Blog 4/03/2024; Inavolisib (Roche)(3.4. Inh PI3K) con palbociclib (Ibrance, Pfizer)(3.7.Inh CDK4/6) y fulvestrant (Faslodex, Astrazeneca)(Anti estrogenos), Blog 3/06/2024; Innocell (PhotonPharma, Inc.)(Vacuna autóloga), Blog 3/04/2024; Isatuximab (Sarclisa, Sanofi)(Anti CD38) más bortezomib (Velcade), lenalidomida (Revlimid), y dexametasona, Blog 3/06/2024;

*JAB-30300 (Jacobio Pharma)(Activ P53 Y220C), Blog 3/04/2024; JCXH-211 IV (Immorna Biotherapeutics)(srRNA), Blog 3/08/2024;

*KME-0584 (Kurome Therapeutics Inc.)(1.4.b.Inh FLT3), Blog 4/03/2024;

*LBS-007 (Lin BioScience)(Inh cicloCel), Blog 3/12/2024; Linvoseltamab (REGN5458, Regeneron)(AcMB BCMA/CD3), Blog 4/03/2024; Lisocabtagén maraleucel (liso-cel, Breyanzi, Juno Therapeutics/Bristol Myers Squibb; FDA, EMA)(CarTAnti CD19), Blog 5/02/2024; Lomonitinib (Eilean Therapeutics LLC.)(1.4.b.Inh FLT3), Blog 3/07/24; LP-184 (Lantern Pharm)(Let Sint), Blog 3/11/2024, 3/10/2024; Lumisight y el Lumicell Direct Visualization System (Lumicell, Inc.), Blog 3/05/2024; Lunresertib (Repare Therapeutics)(17.Otros Inh PKMYT1) con camonsertib(3.b.Inh ATR), Blog 3/07/24; Lutecio (Lu 177) dotatato inyección (Lutetium Lu 177 dotatate injection, Curium)(RadFarm), Blog 3/08/2024; LYT-200 (PureTech Health)(Anti galectina-9) más terapia anti PD-1, Blog 3/05/2024;

*Mirdametinib (D-0325901, SpringWorks Therapeutics, Inc.)(3.2.Inh MEK), Blog 4/09/2024; Mitomicina intravesical (UGN-102, UroGen Pharma Ltd.), Blog 3/11/2024; MVR-T3011 (ImmVira)(Virus oncolítico), Blog 3/04/2024;

*Nivolumab con hialuronidasa humana (Bristol Myers Squibb), Blog 3/06/2024; Nivolumab (Opdivo, Bristol Myers Squibb)(Anti PD-1) más ipilimumab (Yervoy, Bristol Myers Squibb)(Anti CTLA-4), Blog 4/09/2024; Nivolumab (Opdivo, Bristol Myers Squibb; FDA; EMA; España UH)(Anti PD-1) más quimioterapia, Blog 4/03/2024; NK010 (NK CellTech)(aloTerNK), Blog 5/02/2024; NST-628 (Nested Therapeutics)(PegamMolec pan-RAF/MEK), Blog 3/04/2024; NUV-1511 (Nuvation Bio)(ADC), Blog 5/02/2024; NVL-655 (Nuvalent)(1.3.Inh ALK), Blog 3/06/2024;

*Obecabtagén autoleucel (obe-cel, Autolus Therapeutics)(CarTAnti CD19), Blog 5/02/2024; OBX-115 (Obsidian Therapeutics)(Terapia TIL cell), Blogs 3/10/24, 3/08/2024; Olaptesed pegol (TME Pharma)(Inh CXCL12), Blog 3/04/2024; Olaptesed pegol (TME Pharm)(Inh CXCL12) más bevacizumab y radioterapia, Blog 3/05/2024; OriCAR-017 (Oricell Therapeutics)(CarTAnti GPRC5D), Blog 5/02/2024; Osimertinib (Tagrisso, AstraZeneca Pharmaceuticals LP; FDA, EMA, España DH)(1.1.Inh EGFR/HER2), Blog 3/07/24; Ozuriftamab vedotina (BioAtla, Inc.)(ADCanti ROR2), Blog 3/08/2024;

*P-BCMA-ALLO1 (Poseida Therapeutics)(aloCarTAnti TSCM), Blog 3/10/2024; Pembrolizumab (Keytruda, Merck)(Anti PD-1) y carboplatino/paclitaxel, Blog 4/03/2024; Pembrolizumab (Keytruda, Merck Sharp & Dohme; FDA, EMA, España UH)(Anti PD-1) con quimioterapia, Blog 3/06/2024; Plomo (Pb-212) Dotamtato (AlphaMedixTM, RadioMedix y Orano Med)(RadFarm); Plomo (Pb-212) VMT01 (212Pb VMT01, Perspective Therapeutics), Blog 4/10/24; PT217 (Phanes Therapeutics)(AcMB DLL3/CD47), Blog 3/05/2024; PT886 (Phanes Therapeutics, Inc.)(AcMB CLDN18.2/CD47), Blog 3/04/2024;

*RAG-01 (Ractigen Therapeutics)(saRNA), Blog 3/06/2024; RC88 (RemeGen)(ADCanti MSLN), Blog 5/02/2024; Remestemcel-L (Mesoblast Limited), Blog 3/08/2024; Repotrectinib (Augtyro, Bristol Myers Squibb)(1.9.Inh TRK), Blog 4/03/2024; Revumenib (Syndax Pharmaceuticals)(9.Inh Menina), Blog 3/04/2024; R289 (Rigel), Blog 31/12/2024; Rinatabart sesutecan (Rina-S, ProfoundBio)(ADCanti FolRα), Blog 5/02/2024; Rivoceranib (Apatinib, Elevar Therapeutics, Inc.)(1.2.Inh VEGFR2)  y camrelizumab (SHR-1210), Blog 3/11/2024; RP1 (vusolimogén oderparepvec, Replimune Group, Inc.) más nivolumab (Opdivo, Bristol-Myers Squibb Pharma), Blog 3/12/2024;

*Sacituzumab govitecan (Trodelvy, Gilead Sciences, Inc.; FDA (-hziy), EMA, España UH)(ADCanti Trop-2), Blog 31/12/2024; Sacituzumab tirumotecan (SKB264/MK-2870), Blog 31/12/2024; SH-105 (Shorla Oncology), Blog 5/02/2024; SH-201 (Shorla Oncology), Blog 3/05/2024; SLS009 (GFH009, Sellas Life Sciences)(3.7.a.Inh CDK9), Blogs: 3/08/24, 3/07/24, 5/02/2024; SNB-101 (SN Bioscience Co. Ltd.)(Inh ADN topoisom I), Blog 3/06/2024; Sunvozertinib (Dizal Pharma)(1.1.Inh EGFR/HER2), Blog 3/12/2024, 3/05/2024; SynKIR-310 (Verismo Therapeutics)(DS191 CD19.), Blogs 3/12/2024, 3/06/2024;

*Taletrectinib (Nuvation Bio), Blog 31/12/2024; Teclistamab (Tecvayli, Janssen Biotech, Inc./Johnson & Johnson; FDA, EMA, España UH aprobado no comercializado)(AcMB BCMA/CD3), Blog 4/03/2024; Tislelizumab (Tevimbra, BeiGene, Ltd.)(Anti PD-1), Blog 4/03/2024; Tisotumab vedotina (Tivdak, Pfizer/Seagen Inc.; FDA)(ADCanti TF); TLX007-CDx (Telix)(Kit frio Pet-PSMA), Blog 3/08/24; TLX101-CDx (Pixclara, Telix Precision Medicine)(imagen por PET), Blog 3/11/2024; TLX250-CDx (Telix Pharmaceuticals Limited.)(Kit frio Pet-PSMA), Blogs: 3/07/24, 5/02/2024; Trastuzumab deruxtecan (Enhertu; Daiichi Sankyo; FDA, EMA, España UH)(ADCanti HER2), Blog 4/09/2024, 5/02/2024; Trastuzumab deruxtecan (Enhertu, Daiichi Sankyo; FDA (fam-, -nxki), EMA, España UH), Blog 3/11/2024; TSC-100 y TSC-101 (TScan Therapeutics, Inc.)(Anti HA-1/HA-2), Blog 5/02/2024; TTFields (Novocure) más asistencia estándar, Blog 4/03/2024;

*UB-VV111 (Umoja Biopharma, Inc.)(CarTAnti CD19), Blog 4/09/2024; UCART22(alogCarTAnti CD22) (Cellectis), Blog 3/08/24; UGN-103 (UroGen Pharma Ltd.)(Gel Mitom), Blog 3/05/2024; UV1 (Ultimovacs ASA)(Vac antiTelomerasa) con ipilimumab (Yervoy, Bristol Myers Squibb) y nivolumab (Opdivo, Bristol Myers Squibb; FDA; EMA; España UH), Blog 4/03/2024;

*VCN-01 (Theriva Biologics, Inc.)(Adenovirus oncolítico), Blog 4/09/2024; VCN-01 (Theriva biologics) con gencitabina y nab-paclitaxel, Blog 3/06/2024; Vepdegestrant (Arvinas y Pfizer)(Anti estrogenos), Blog 4/03/2024; VLS-1488 (Volastra Therapeutics)(Inh KIF18A), Blog 3/11/2024; Vimseltinib (DCC-3014, Ono Pharmaceutical, Co., Ltd.)(1.4.a.Inh CSF1R), Blog 4/09/2024; VNX-101 (Vironexis Biotherapeutics)(Vir AAV), Blogs 3/10/24; Vorasidenib (Voranigo, Servier Pharmaceuticals LLC)(8.1.Inh IDH1/2), Blog 4/03/2024;

*WGc-043 (WestGene)(Vac ARNm), Blog 3/06/2024;

*Zanidatamab (Jazz Pharmaceuticals plc.)(AcMB HER2/HER2), Blog 3/06/2024; Zenocutuzumab (Merus)(AcMB HER2/HER3), Blog 3/06/2024; Ziftomenib (Kura Oncology)(9.Inh Menina), Blog 3/05/2024; Zolbetuximab (Vyloy, Astellas Pharma Inc.)(Anti CLDN18.2), Blog 3/06/2024; Zongertinib (Boehringer Ingelheim)(1.1.a.Inh HER2), Blog 4/09/2024;